Pharma Marketletter - Merck & Co’s Cozaar gets US approval for stroke prevention.
Merck & Co’s angiotensin II receptor antagonist Cozaar (losartan) has become the first and only antihypertensive to be approved in the USA for reducing the risk of stroke in patients with high blood pressure and left ventricular hypertrophy, which can be a precursor to heart failure. However, new labeling for the product indicates that this …
Related Results
Merck & Co’s Cozaar gets US approval for stroke prevention.
Panel adds to uses for drug. (Digest).(Cozaar approved as therapy for reducin…
Merck Reports First-Quarter 2008 Financial Results
Bellwether Report.com is Looking at Merck & Co. Inc.
Hypertensive drug classes: brand names only
Want to read the whole article? You can purchase it here. It’s quick and easy.
